Moderna Inc.’s Covid-19 vaccine produced antibodies to the coronavirus in all patients tested in an initial safety trial, federal researchers said, clearing an important milestone as the U.S. continues to grapple with a surge in new infections.
The U.S. biotech firm’s breakthrough is one of the most promising developments yet in the race to develop a vaccine against the virus that has paralyzed the world’s economy. The stock jumped in…